Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded
- Contract number
- SPE2DR26FMDW1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $79,696
Award facts
- Contract value 100% obligated
- $79,695.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $79,695.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 10, 2025, with an ultimate completion date of November 12, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's recently awarded single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling value and extends through December 31, 2036.
DMS Pharmaceutical Group has demonstrated substantial capability as a federal pharmaceutical supplier, with the company registered in the System for Award Management since July 2001 and maintaining consistent performance across multiple therapeutic categories. As a critical supplier within the Department of Defense's global pharmaceutical supply chain, the company distributes an extensive portfolio of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to military healthcare facilities worldwide. The PPV-G GEN V contract under which this delivery order is issued represents a $30.3 billion acquisition strategy designed to ensure recurring medical supply support across the military health system, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors serving this strategic function.
Quick answers
Who was awarded contract SPE2DR26FMDW1?
SPE2DR26FMDW1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 10, 2025.
How much is contract SPE2DR26FMDW1 worth?
The government has obligated $79,696 on SPE2DR26FMDW1.
Is contract SPE2DR26FMDW1 an order under another contract?
Yes. SPE2DR26FMDW1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDW1 competed?
The extent of competition for SPE2DR26FMDW1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award